Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA against AFTPH is a research-grade small interfering RNA designed to silence the expression of the Aftiphilin (AFTPH) gene. AFTPH is a protein involved in membrane trafficking and is a downstream target of microRNA-133a; its expression is notably reduced in colonic tissues of patients with ulcerative colitis and in experimental colitis models. In vitro studies using human colonic epithelial cells (such as NCM460) have demonstrated that transient silencing of AFTPH leads to impaired epithelial barrier function and altered actin organization, characterized by a decreased F-/G-actin ratio and activation of the p70S6K kinase. This siRNA serves as a critical tool for investigating the molecular mechanisms of intestinal homeostasis and the pathophysiology of inflammatory bowel diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on siRNA against AFTPH.